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Abstract
Four methodologies were evaluated for quantifying kilovoltage cone-beam com-
puted tomography (CBCT) dose: the Cone-Beam Dose Index (CBDI), IAEA Report 5
recommended methodology (IAEA), the AAPM Task Group 111 methodology
(TG111), and the current dose metric; the Computed Tomography Dose Index
(CTDI) on two commercial Varian cone-beam CT imaging systems; the Clinac iX On-
Board Imager (OBI); and the TrueBeam X-ray Imaging system (XI). The TG111
methodology measured the highest overall dose (21.199  0.035 mGy OBI and
22.420  0.002 XI for pelvis imaging) due to the full scatter of the TG111 phantom
and was within 5% of CTDI measurements taken using a full scatter TG111 phan-
tom and 30-cm film strips. CBDI measured the second highest overall dose, within
10% of the TG111, with IAEA measuring the third highest dose. For head CBCT
protocols, CBDI measured the highest dose, followed by IAEA. The CTDI method
measured lowest across all scan modes highlighting its limitations for CBCT dosime-
try. The XI imaging system delivered lower doses for head and thorax scan modes
and similar doses to the OBI system for pelvis scan modes due to additional beam
hardening filtration in the XI system. The TG111 method measured the highest dose
in the center of a CBCT scan during image guidance procedures; however, CBDI
provided a good approximation to TG111 with existing CTDI equipment and may
be more applicable clinically.
P A C S
87.57.Q- Computed tomography, 87.57.uq Dosimetry
K E Y WORD S
computed tomography dose index, cone beam computed tomography, gafchromic film, image
guided radiotherapy, radiotherapy
1 | INTRODUCTION
Modern radiotherapy has seen an increase in use of modulated dose
delivery techniques such as intensity-modulated radiation therapy
(IMRT), volumetric modulated arc therapy (VMAT), and tomotherapy.
With these new methods, the prescribed treatment dose can be
delivered to the target with a high degree of conformity, while a
steep dose gradient minimizes the dose to surrounding healthy tis-
sue. It follows that variation in patient setup, anatomy, or movement
during the course of treatment can lead to deviations in dose deliv-
ered to both the tumor and surrounding tissue from the original
treatment plan. Hence, verification of patient setup at treatment is a
fundamental step in ensuring precision in the delivery of
radiotherapy.
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Image guidance for patient positioning was originally performed
using the megavoltage (MV) treatment beam and an electronic portal
imaging device (EPID) or film placed behind the patient. However, at
these MV energies, the inherent Compton scatter results in poor
soft-tissue contrast, limiting reference points within the body to
higher Z tissue such as bone, or internal fiducial markers. To resolve
this, many linear accelerators (LINACs) now have built-in kilovoltage
(kV) imaging systems that can produce images with improved soft-
tissue contrast to correct for internal organ motion and patient setup
errors. Examples include the On-Board Imager (OBI) and the True-
Beam X-ray imaging system (XI) of Varian Medical Systems (Palo
Alto, CA, USA). These devices consist of a kV X-ray source and an
amorphous silicon detector mounted to the LINAC gantry on
extendable robotic arms orthogonal to the treatment beam. These
devices can acquire 3D cone-beam CT (CBCT) images of the patient
in a single rotation of the gantry allowing registration with the radio-
therapy planning CT to check for positional errors and make correc-
tions as necessary with a high degree of accuracy.1,2
Currently, imaging dose is often omitted from treatment plans
since, being typically less than 1 Gy for an entire treatment sched-
ule or 1–10 cGy for a single scan, it is two orders of magnitude
smaller than the therapeutic doses.1,3–9 However, during an imaging
procedure, large portions of the body are irradiated, including
radiosensitive structures such as lung, breast, thyroid, and reproduc-
tive organs. Bone structures also receive higher doses than other
tissue at kV energies due to increased photoelectric absorption.
Simulated doses in the femoral heads as high as 1.5–2.5 Gy have
been reported due to daily pelvis CBCT imaging during a course of
radiotherapy.10
Each clinic has its own protocols for frequency of CBCT imaging
depending on tumor site and experience in day-to-day setup varia-
tions. While some radiotherapy clinics use daily CBCT imaging, often
a typical CBCT schedule might be daily for the first week then once
per week for the remainder of the treatment course. During a treat-
ment of 30–40 fractions, the imaging dose has been shown to be
significant, with reported effective doses of between 8 mSv and
46 mSv per CBCT scan leading to an increased risk of a patient
developing a secondary primary malignancy.1,11,12 Therefore, a
method for quantifying the imaging dose is necessary to evaluate
any increased risk to the patient and aid in making informed deci-
sions on the appropriate use of CBCT imaging during the course of
treatment.
The traditional methods for quantifying fan-bean CT dose, the
Computed Tomography Dose Index (CTDI), underestimate CBCT
dose due to an insufficient detector length to capture the full dose
profile, and inadequate phantom length to achieve scatter equilib-
rium in the center of the detector.13 The underestimation worsens
with increased beam width, which can be up to 40 cm for CBCT
scans.14 Three alternative protocols have emerged in recent years
which attempt to better quantify the imaging dose for wide beam
scanning: The Cone-Beam Dose Index (CBDI);14 The International
Atomic Energy Agency (IAEA) Human Health Report No. 5;15 and
the American Association of Physicists in Medicine (AAPM) Task
Group 111 Report.16 While each protocol attempts to account for
the limitations of CTDI in determining CBCT dose, their approach is
somewhat different in terms of both equipment and measurement
conditions. A comparison of all four methodologies for measuring
CBCT dose forms the scope of this paper.
2 | METHODS
2.A | Phantom design and materials
A standard 32-cm-diameter poly methyl methacrylate (PMMA) CTDI
body phantom and 16-cm-diameter head phantom were used for
CTDI, CBDI, and IAEA measurements as shown in Fig. 1. Both phan-
toms have insert spaces for a 100-mm pencil ionization chamber at
the center and at the four peripheral locations. The phantom was
placed on the couch with the center positioned at the isocenter
using the room alignment lasers.
CTDI and CBDI measurements were taken using the UNFORS
Xi detector system from RaySafeTM. The system includes a base unit
which connects to several detectors including a CT detector and
HVL measurement tool for kV energies. The pencil ionization cham-
ber for CT measurement has a sensitive length of 100 mm. The Xi
device is a self-contained detector, including the ionization cham-
ber, electronics, and automatic temperature and pressure adjust-
ments. The detector has a dose range of 10 lGy to 9999 Gy with
an uncertainty of 5%. Its energy dependence is <5% with an axial
and radial uniformity of 2% and 3%, respectively.
F I G . 1 . PMMA 32-cm CTDI body phantom with the pencil
chamber in the central position. For head protocols, the 16-cm inner
phantom was used.
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To fulfill the scatter requirements of the TG111 protocol, a new
phantom was designed with a length of 45 cm [Fig. 2(a)]. The phan-
tom was constructed from PMMA with the same 32 cm diameter as
the CTDI phantom and five holes drilled into the phantom under the
same center and peripheral configuration as the CTDI style measure-
ments. During measurement, the ionization chamber was placed in
one location, while the other four holes were filled with cylindrical
PMMA plugs. The ionization chamber was housed in a customized
plug, shown in Fig. 2(b), built to conform to the Farmer chamber
geometry and eliminate air gaps around the sensitive volume.
The chamber used for the TG111 measurements was a 0.6-cc
NE 2571 Farmer ionization chamber. The sensitive air volume has a
length of 24 mm and radius 3.2 mm. It is enclosed by a graphite
thimble of thickness 0.065 g/cm2. The chamber operates at a bias
voltage of 300 V between the stem and chamber wall. The chamber
was calibrated at the Australian Radiation Protection and Nuclear
Safety Agency (ARPANSA) and is traceable to the Australian primary
standard.
2.B | OBI and XI CBCT imaging systems
Measurement of CBCT dose was performed on both a Varian 21iX
on-board imaging (OBI) and Varian TrueBeam X-ray imaging (XI) sys-
tems. Each system can acquire 2D kV and 3D CBCT images as the
source and detector are rotated around the patient. The clinical
CBCT protocol settings used for the measurements in this study are
given in Table 1.
The beam width is modulated with independently adjustable X-
and Y-lead blade collimators. The field size at isocenter can be varied
from 2.0 9 2.0 mm to 50.0 9 50.0 cm on both the XI and OBI sys-
tems. The X1 and Y1 collimators have a range of 25.0 to +3.5 cm
and the X2, Y2 from 3.5 cm to +25 cm. On the XI system, a tita-
nium beam hardening foil filter further hardens the X-ray spectrum
to reduce low-energy photons. The axial plane is further modulated
with an aluminum bow tie filter varying in thickness from 2 to
28 mm.
2.C | Determining the CTDI and CBDI
Dose for a CBCT scan was measured with the pencil chamber placed
sequentially in each position within the phantom. This dose value
represents the average dose across the 100 mm length, and multi-
plying by the chamber length (Lc) yields the dose-length integral
(DLI):
DLIðmGy mmÞ ¼ Lc  Dmeasured (1)
where DMeasured represents the measured dose collected in scanning
length Lc = 100 mm. To obtain the CTDI, the DLI is divided by the
superior–inferior (S–I) collimation width (coll):
CTDIðmGyÞ ¼
1
coll
DLI (2)
The CBDI is calculated by dividing the DLI by the 100 mm sensi-
tive length of the chamber Lc:
(a) (b)
F I G . 2 . (a) The custom-built TG111
phantom with a longitudinal length of
45 cm produces scatter equilibrium in the
phantoms’ center. The cylindrical diameter
of 32 cm is equivalent to the CTDI
phantom and contains five plugs for
weighted measurements. (b) Plug for
housing the 0.6-cc Farmer ionization
chamber in the TG111 phantom. The plug
contains three sections, one to run the
cable out of the phantom, a middle section
milled to conform to the chamber
geometry, and a solid front section to fill
the remaining air gap in the bore hole.
TA B L E 1 kV, mAs, and collimator settings for the clinical modes
tested in the OBI and XI imaging systems.
Protocol kV mAs
Superior–inferior
(S–I) collimation (cm)
Axial collimation
(cm)
Pelvis OBI 125 680 20.6 30.3
Pelvis XI 125 1056 21.4 28.1
Thorax OBI 110 262 20.6 30.3
Thorax XI 125 262 21.4 28.1
OBI high head 100 720 18.4 27.2
OBI std head 100 145 18.4 27.2
OBI low head 100 72 18.4 27.2
XI head 100 145 21.4 28.0
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CBDIðmGyÞ ¼
1
Lc
DLI (3)
Weighted CTDIw and CBDIw were then calculated from
the CTDIc measured in the center of the CTDI phantom and
average of CTDI measurements in the peripheral positions
CTDIp:
CTDIw ¼
1
3
CTDIc þ
2
3
CTDIp (4)
The normalized nCTDIw and
nCBDIw values, which represent
CTDIw per 100 mAs, were determined from the weighted CTDIw
values and corresponding mAs for the given scan:
nCTDIw ¼
CTDIw  100
mAs
(5)
The CBDI methodology proposed by Amer et al. stipulates addi-
tional scatter material be placed superior and inferior to the CTDI
phantom to achieve scatter equilibrium in the center of the phan-
tom. In this study, no additional scatter material was used for CBDI
measurements. It should be noted that this will result in a reduction
in measured dose, as reported by Amer et al.14
2.D | IAEA methodology
The weighted IAEAw dose was determined for the clinical protocols
for pelvis, thorax, and head CBCT. As per the IAEA protocol for
beam widths greater than 60 mm, a reference CTDIref is first deter-
mined with a S–I collimation of 2 cm. The CTDIref is an in-phantom
CTDI measurement with sufficiently narrow S–I collimation to facili-
tate the capture of the full dose profile by the 100-mm pencil cham-
ber within the CTDI phantom. The CTDIref is scaled by the ratio of
CTDI, measured in free-air, with S–I collimations of 2 cm and that
used in the clinical protocol, to give IAEAw as outlined in eq. (6):
IAEAw ¼ CTDIref 
CTDIinairprotocolwidth
CTDIinairreferencewidth
 !
(6)
The free-air measurements were taken with the pencil chamber
suspended away from the couch as shown in Fig. 3. The kV, mAs,
and axial collimation settings specified by the clinical protocol were
applied for all measurements.
For free-air measurements taken at the clinical CBCT S–I collima-
tion, the IAEA specifies a minimum measurement length of the S–I
collimation width + 40 mm, or 20 mm either side of the beam. For
half-fan protocols, the beam widths were 206 mm and 214 mm for
the OBI and XI systems, respectively, corresponding to minimum
measurement lengths of 246 mm and 254 mm. To achieve the
required length, the pencil ionization chamber was stepped through
the beam in three increments for a total measurement length of
300 mm. Preliminary measurements showed that even for a mea-
surement length of 300 mm, a small fraction of the dose profile was
being missed, likely due to scatter from the collimators. Hence, for
clinical CBCT S–I collimation widths, the chamber was stepped
through the beam in five increments for a total measurement length
of 500 mm to capture the full dose profile.
The DLI for each chamber position was summed and divided by
the S–I collimation to yield the protocol width CTDIin-air:
CTDIinairprotocol width ¼
P5
i¼1 DLIi
coll
(7)
2.E | AAPM TG111 methodology
The TG111 methodology for calculating CBCT dose is based on
measuring dose in a phantom that provides close to full scattering
conditions for broad cone-beam imaging systems.16 As such, the
custom-built phantom described in Section A was used to deter-
mine a weighted TG111w dose for the pelvis and thorax clinical
CBCT protocols on both the OBI and XI systems. A separate head
phantom was not constructed for our study, and hence, CBCT dose
measurement using the TG111 approach was limited to the full
360° gantry rotation protocols. Dose was measured with a Farmer-
type cylindrical ionization chamber positioned centrally in the S–I
axis of the phantom with the sensitive volume aligned to the
isocenter. Similar to the CTDI measurements, TG111w is deter-
mined by measuring dose at the center and four peripheral posi-
tions in the phantom.
The Farmer chamber used is traceable to the Australian primary
dose standard through a series of air KERMA calibration factors (NK)
for beams of a known HVL (Table 2). The HVL of the OBI and XI kV
F I G . 3 . Experimental setup for the measurement of CTDIin-air. The
100-mm chamber was stepped in 100-mm increments to achieve
the necessary integration length to capture the full dose profile. The
chamber was held in place using a retort stand and rod. The
chamber was extended from the couch a distance equal to half the
total integration length to minimize scatter from the couch as
specified by the IAEA.15
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beams had previously been measured with the UNFORS detector.
The accuracy of the UNFORS to measure HVL was verified on an
orthovoltage unit for several beam qualities with well-known HVL
values. The charge collected (q) in the ionization chamber was cor-
rected for ambient temperature and pressure and converted to dose
using eq. (8):
Dw  qNK
l
q
 material
air
(8)
where l
q
 material
air
represents the ratio of spectrally averaged mass
energy–absorption coefficients of the phantom material to air. For
simplicity, and to be consistent with IAEA dose formalisms in diag-
nostic radiology,17 doses are quoted as dose to air and hence
l
q
 material
air
¼ 1.
2.F | Comparison of methodologies for increasing
beam width and film measurements
To further investigate the limitations of the use of CTDIs for CBCT
dosimetry, the four methodologies were evaluated for increasing S–I
collimation widths. Measurements were taken at collimation widths
of 2, 5, 10, 15, 20.6, 25, and 40 cm using the OBI clinical CBCT pel-
vis protocol. The S–I collimation setting for the OBI pelvis protocol
of 20.6 cm was used in place of the standard 20-cm measurement.
The distance between successive measurements was increased for
wider beams as scatter equilibrium was approached, and further
increases in dose were minimal for the wider collimation widths.
CTDIw, IAEAw, CBDIw, and TG111w values were determined at each
collimation width.
The CBCT doses measured with the four different methodologies
were also compared to a CTDI style integrated dose measurement
CTDIfilm using Gafchromic XR-QA2 film. The film is sensitive in the
energy range 20–200 kVp and a dose range of 0.1–20 cGy. The film
consists of a 97-lm polyester layer, 20-lm adhesive layer, 25-lm
active layer, and a 97-lm white polyester backing layer. Due to the
strong energy dependence of the film for low energies, separate cali-
brations were performed for the OBI and XI imaging systems.18–20
The film was scanned prior to and 24 h postexposure on an
Epson Expression 10000 XL flatbed scanner at 72 dpi resolution in
48-bit color RGB mode. The scanner was operated in reflection
mode with all corrections switched off. The images were analyzed in
the red channel as this encompass the wavelength component asso-
ciated with the most change in film color.21
The film was calibrated against air KERMA measured with a 0.6-
cc Farmer chamber with calibration traceable to a primary standard.
To avoid changes in film response due to beam rotation, dose cali-
bration for the film was performed in kV fluoroscopy mode with a
stationary X-ray tube.19,22 The kVp, mAs, and collimator widths were
set to be identical to the pelvis CBCT protocol for the calibration.
Furthermore, the bow tie filter was inserted in place to ensure that
the calibration was performed in the same beam quality as the CBCT
beam.
The film was analyzed in ImageJ (National Institute of Health,
Bethesda, MD, USA) and average pixel intensity across a 1 9 2 cm
region of interest (ROI) for each piece used to determine net reflec-
tance (net DR) using a method previously described by Tomic et al.23
The data were imported into MATLAB (MathWorks Inc., Natick,
MA, USA) and a curve fit to the data. The applied fitting function
was of the form y ¼ ax
bx where x and y represent net DR and air
KERMA, respectively, with corresponding fitting parameters a and b.
A fitting function of this form has the benefit of being monotonically
increasing and returns a zero value for zero dose.
For CTDIfilm measurements, 30 cm by 3 cm film strips were cut
to measure the full length of the beam profile. A custom-built
PMMA cylindrical rod designed to fit in the holes of the TG111
phantom was created to house the film strips. The rod was cut into
two hemispheres allowing the film to be placed in between the
hemispheres before inserting the rod into the phantom. Individual
strips were then exposed in each of the five positions within the
TG111 phantom on OBI and XI systems. Two CBCT scans were
acquired for each strip to deliver a higher dose to the film. The film
processing and scanning procedure described earlier for the film cali-
bration were maintained for the film strips. Line profiles were taken
across the film strips and converted to air KERMA using the respec-
tive calibration curves. The converted air KERMA values were then
halved to obtain the dose profile for a single CBCT scan. Due to the
high sensitivity of XR-QA2 film, two strips were irradiated and an
average profile calculated. The center and peripheral DLIs were
determined from the film profiles and divided by S–I collimation to
yield the CTDIfilm which was compared to TG111w measurements
on the OBI and XI systems.
3 | RESULTS
3.A | CTDI AND CBDI MEASUREMENTS
Weighted CTDIw and normalized
nCTDIw dose for OBI and XI clinical
protocols are shown in Table 3 with weighted CBDIw and normal-
ized nCBDIw dose shown in Table 4.
CTDIw values were similar for OBI and XI pelvis protocols with
XI measuring 0.24 mGy (3%) higher. The OBI thorax mode measured
0.23 (10%) mGy higher than the XI thorax mode. The varying mAs
across the three OBI head modes were reflected in the respective
doses, which varied by 10.17 mGy. OBI standard head mode mea-
sured 0.59 (36%) mGy higher than the XI head mode.
TA B L E 2 HVL and corresponding NK values for the 2571 Farmer
chamber. NK values were determined from a curve fit of the
calibration certificate HVL to NK data.
Protocol
HVL
(mm Al)
Correction factor
NK (mGy nC
1)
OBI pelvis 5.84 41.618
XI pelvis 8.43 41.591
OBI thorax 5.20 41.629
XI thorax 8.23 41.560
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The normalized nCTDIw dose was higher for the OBI system
across pelvis, thorax, and head protocols. In particular, the pelvis
modes varied by 0.47 (43%) mGy. The difference is attributed to the
higher mAs for pelvis scans on the XI system which is offset by its
additional beam hardening titanium filter.
The trends described above for CTDIw and
nCTDIw dose also fol-
low for CBDI as the CBDI simply upscales CTDI by dividing by
chamber length rather than S–I collimation. Due to the upscaling, the
CBDI values are more than double CTDI with an increase of 106%
for OBI and 114% for XI protocols. These values would be higher
still had additional scatter material been used for the CBDI.14
3.B | IAEA MEASUREMENTS
The CTDIin-air dose and their ratios for the OBI and XI systems are
presented in Table 5 and the weighted IAEAw and normalized
nIAEAw doses in Table 6. The OBI thorax mode could not be evalu-
ated for the IAEA method as the UNFORS chamber would not trig-
ger for reference beam width scans due to the low signal.
The average in-air ratio for the OBI system was 16% higher than
for the XI system. The difference between OBI and XI systems is
due to additional filtration in the XI system which removes low-
energy photons from the spectrum. Hence, the photon fluence in air
is higher in the OBI system, and more energy is deposited within the
pencil chamber.
The weighted pelvis IAEAw was 3.57 (24%) mGy higher for the
OBI system compared with XI. The OBI standard head mode was
0.937 (33%) higher than the XI head mode. The higher OBI values
reflect the greater variation in dose measured between the refer-
ence beam width and protocol width resulting in a larger in-air
ratio for the OBI protocols when compared with the XI ones.
These differences in ratios may partially be attributed to the addi-
tional low-energy photon component that is filtered out by the
titanium filter on the XI system. Normalized nIAEAw values varied
by 1.30 (93%) mGy 100 mAs1 and 0.04 (35%) mGy 100 mAs1
across pelvis and head modes, respectively.
3.C | TG111 MEASUREMENTS
The weighted TG111w and normalized
nTG111w doses for pelvis and
thorax modes on the OBI and XI systems are given in Table 7.
The XI pelvis mode measured the highest dose, 1.22 (6%) mGy
higher than the OBI pelvis protocol. The higher dose for XI can be
attributed to a slightly larger transverse collimation width and a higher
mAs. When normalized per 100 mAs, the OBI system delivered an
additional 1.00 (47%) mGy compared with the normalized XI pelvis
mode.
The OBI system measured 1.42 (26%) mGy higher than XI for the
respective thorax modes and 0.56 (27%) mGy higher than XI for
TA B L E 4 Calculated CBDIw and
nCBDIw values for clinical CBCT
modes on the OBI and XI systems. Uncertainties represent one
standard deviation from repeated measurements.
Clinical scan mode CBDIw (mGy)
nCBDIw
(mGy 100 mAs1)
OBI pelvis 19.381  0.135 2.850  0.020
XI pelvis 20.642  0.113 1.955  0.011
OBI thorax 5.225  0.013 1.994  0.005
XI thorax 4.927  0.021 1.880  0.008
OBI high-dose head 23.380  0.106 3.247  0.015
OBI std-dose head 4.605  0.038 3.176  0.026
OBI low-dose head 2.439  0.033 3.388  0.046
XI head 3.527  0.020 2.432  0.014
TA B L E 5 Calculated CTDIreference and CTDIprotocol in-air values for
clinical CBCT modes on the OBI and XI systems.
Clinical scan mode
CTDIreference
width (mGy)
CTDIprotocol
width (mGy) Ratio
in-air
OBI pelvis 57.88 74.04 1.28
XI pelvis 67.10 69.13 1.03
XI thorax 16.42 16.94 1.03
OBI high-dose head 38.73 47.33 1.22
OBI std-dose head 7.89 9.49 1.20
OBI low-dose head 4.08 5.02 1.23
XI head 5.11 5.29 1.04
TA B L E 6 Calculated weighted IAEAw and normalized
nIAEAw values
for clinical CBCT modes on the OBI and XI systems. Uncertainties
represent one standard deviation from repeated measurements.
Clinical scan mode
Weighted IAEAw
(mGy)
Normalized nIAEAw
(mGy 100 mAs1)
OBI pelvis 18.343  0.001 2.698  0.001
XI pelvis 14.771  0.006 1.399  0.001
XI thorax 4.441  0.206 1.682  0.078
OBI high-dose head 15.316  0.140 2.127  0.019
OBI std-dose head 3.747  0.278 2.584  0.192
OBI low-dose head 1.726  0.003 2.397  0.004
XI head 2.810  0.109 1.912  0.075
TA B L E 3 Calculated CTDIw and
nCTDIw values for clinical CBCT
modes on the OBI and XI systems. Uncertainties represent one
standard deviation from repeated measurements.
Clinical scan mode CTDIw (mGy)
nCTDIw
(mGy 100 mAs1)
OBI pelvis 9.408  0.065 1.384  0.010
XI pelvis 9.646  0.053 0.913  0.005
OBI thorax 2.536  0.006 0.968  0.002
XI thorax 2.302  0.010 0.879  0.004
OBI high-dose head 11.349  0.058 1.576  0.008
OBI std-dose head 2.236  0.021 1.542  0.014
OBI low-dose head 1.184  0.019 1.644  0.025
XI head 1.648  0.010 1.137  0.007
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normalized nTG111w. Both the OBI and XI systems deliver 262 mAs for
thorax scanning; however, due to the titanium filter in the XI system,
the fluence is higher in the OBI systemwith subsequently higher dose.
3.D | COMPARISON OF METHODOLOGIES
Comparisons of TG111, CBDI, IAEA, and CTDI protocols for pelvis
and thorax protocols are illustrated in Fig. 4(a) and 4(b). Comparison
of CBDI, IAEA, and CTDI for head protocols are shown in Fig 4(c).
The TG111 methodology resulted in the highest recorded dose for
the pelvis and thorax CBCT protocols. The CBDI methodology pro-
duced the second highest dose followed by the IAEA methodology,
while the CTDI method yielded the lowest dose for each protocol. For
pelvis modes, the CTDIw measured 56% and 57% lower than TG111w
for OBI and XI, respectively, and similarly 64% and 58% lower for the
thorax protocols.
For the head protocols and noting the absence of a TG111 mea-
surement, the CBDI measured the highest dose, followed by IAEA
and CTDI for the standard head OBI mode and XI head mode. The
CTDIw measured 106% and 114% lower than CBDIw for OBI and XI
head protocols, respectively.
3.E | COMPARISON OF METHODOLOGIES
FOR INCREASING BEAM WIDTH
Weighted doses from CTDI, CBDI, IAEA, and TG111 protocols for S–I
collimation widths ranging from 2 cm to 40 cm are presented in Fig. 5.
The CTDI method yielded the highest dose for small beam widths with
a peak value of 15.1 mGy at 5 cm. Further increases in beam width
from 10 cm onward saw a decline in the CTDI such that a collimator
width of 40 cm results in a CTDI dose value of 5.0 mGy. The IAEA
method was equivalent to the CTDI for beam widths less than 10 cm.
The IAEA reached a maximum of 18.5 mGy at 15 cm beam width and
did not increase for beam widths beyond 15 cm. The CBDI method
recorded the lowest dose for beam widths less than 10 cm as the mea-
sured dose is divided by the 10 cm chamber length, rather than the
collimation width. At 10 cm beam width, the CBDI and CTDI both
measured 14.2 mGy. The CBDI continued to increase asymptotically
with a maximum value of 20.2 mGy at 40 cm collimation width. The
TG111 method measured the second lowest dose for collimation
widths less than 10 cm. At 10 cm beam width, the TG111 and IAEA
methods agreed within 0.4 mGy. For wider collimation, the TG111
method increased asymptotically, but the increase continued for larger
collimations compared to the CBDI due to the increased scatter pro-
vided by the 45 cm phantom. The TG111 reached a maximum value of
22.4 mGy at 40-cm collimation width.
Film profiles measured in the center and periphery of the TG111
phantom are shown in Fig. 6(a) for the OBI system and Fig. 6(b) for
the XI system. The weighted CTDIfilm values calculated from the film
profiles for the OBI and XI systems are given in Table 8 along with
the TG111w values for comparison. The CTDIfilm were within 3%
and 5% of the TG111w values for the OBI and XI systems, respec-
tively. The film-based doses were lower than the ionization chamber
TG111w doses in both cases.
4 | DISCUSSION
The TG111 methodology yielded the highest dose for pelvis and
thorax CBCT protocols for both the OBI and XI systems. The higher
TA B L E 7 Calculated TG111w and
nTG111w values for pelvis and
thorax clinical protocols on the OBI and XI imaging systems.
Uncertainties represent one standard deviation from repeated
measurements.
Clinical scan mode TG111w (mGy)
nTG111w
(mGy 100 mAs1)
OBI pelvis 21.199  0.035 3.122  0.005
XI pelvis 22.420  0.002 2.123  0.001
OBI thorax 6.963  0.003 2.658  0.001
XI thorax 5.540  0.001 2.098  0.001
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F I G . 4 . Comparison of TG111, CBDI, IAEA, and CTDI
methodologies on the OBI and XI imaging systems for pelvis (a) and
thorax (b) protocols. The IAEA was not evaluated for OBI thorax.
Comparison of CBDI, IAEA, and CTDI methodologies for OBI
standard head and XI head protocols is shown in (c). Error bars
represent one standard deviation from repeated measurements.
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TG111 doses are attributed to the longer TG111 phantom producing
full scatter conditions. The approach to scatter equilibrium measured
in the center of the phantom is observed in Fig. 5 for increasing col-
limation widths where TG111w approaches a dose maximum at the
largest S–I collimation width.
The CBDI method utilizing the existing CTDI phantom and pencil
chamber demonstrated good agreement with the TG111 results for
beam widths 10 cm and greater. However, as the collimation width of
the beam increased beyond the 16 cm phantom length, a separation
of the data points between the two methodologies is apparent (Fig. 5).
The lower CBDI results at large collimator widths are attributed to the
loss of scatter material beyond the edge of the phantom. In the origi-
nal study by Amer et al., when additional scatter material was placed
at either end of the CTDI phantom, an increase of 31% and 8% at the
center and periphery in CBDI was recorded, respectively.14
The IAEA approach captured the full dose profile in air which
resulted in a higher value for CBCT dose compared with CTDI and,
unlike CTDI, did not decrease for increasing beam width. The IAEA
approach does underestimate the dose for CBCT scanning compared
to TG111 and CBDI as it does not account for the contribution of
scatter beyond the phantom for wide beams. The largest variation
between IAEA with CBDI and TG111 was seen at the greatest colli-
mation widths where scatter equilibrium was approached in the full-
length phantom. This is in contrast to the results from Hu and
McLean, who reported in-air correction factors of less than 1, which
resulted in IAEA values more representative of CTDI.7 They con-
cluded the IAEA method did not correct for efficiency losses due to
the full beam width not being captured. A possible explanation could
be the 300 mm in-air integration length used by Hu for protocol
width scans which did not capture the full dose profile. During our
study, we found a 500 mm integration length was necessary to cap-
ture the full dose profile which was likely due to scattered photons
from the collimators extending past the 300 mm integration length.
Additionally, DLI calculated with a 300-mm ionization chamber used
in the Hu study averages dose across the full integration length,
while for our approach, the dose integral was acquired from a sum-
mation of five dose integrals for each step of the pencil chamber.
Lower doses at the ends of 300-mm sensitive-length chamber would
reduce the average dose compared with a stepwise approach for
which far ends of the detection length were weighted, in this case
by 1
5
of the dose integral as shown in eq. (7).
The CTDI values were significantly lower than the doses measured
by the three alternative methodologies across all CBCT clinical protocols.
Compared to TG111w, dose differences between 55% and 64% were
observed for pelvis and thorax protocols across OBI and XI systems. The
underestimation is due to an insufficient detector length to capture the
full dose profile and a phantom without the required length to achieve
full equilibrium scatter. The underestimation worsens with increasing
beam width as the divisor in the CTDI calculation increases with minimal
increase in the measured dose profile. This supports previous work from
Boone who showed CTDI100 had an efficiency of 63% compared with
CTDI with infinite detection and phantom length.13 Hu and McLean
showed a 66% efficiency of a 100 mm integration length compared to a
300-mm integration.7 Hu also demonstrated a dose difference of up to
36% between a 16-cm phantom and 45-cm phantom.
The slightly higher TG111w measurements for the pelvis XI sys-
tem compared to pelvis OBI were due to the higher mAs used for
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F I G . 6 . Film profiles in the center and peripheral positions within
the TG111 phantom for OBI (a) and XI (b) systems.
TA B L E 8 Calculated CTDIfilm values and TG111w values in mGy for
OBI and XI systems. Uncertainties represent one standard deviation
from repeated measurements.
CBCT system Weighted CTDIfilm (mGy) TG111w (mGy)
Pelvis OBI 20.47  0.71 21.20  0.01
Pelvis XI 21.28  0.44 22.42  0.01
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F I G . 5 . Weighted CTDI, CBDI, IAEA, and TG111 methodologies
for increasing S–I collimation. The beam width was increased from
2 cm to 40 cm and was acquired on the OBI pelvis CBCT mode.
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the XI system. The higher mAs in the XI system is offset by the
beam hardening titanium foil filter which removes low-energy pho-
tons from the X-ray spectrum to reduce skin dose and improve sig-
nal-to-noise ratio. The normalized nTG111w values were higher for
the OBI system. For thorax protocols, the OBI system delivered a
higher dose than the XI system, where 262 mAs was used in both
protocols. The higher nTG111w pelvis mode and TG111w thorax
mode doses for the OBI system can be attributed to the low-energy
photons present in the OBI beam.
The calculated CTDIfilm dose showed good agreement (5% for XI
and 3% for OBI) with the TG111w values for both the OBI and XI
systems. This result is consistent with the 3% agreement reported
by Hu and McLean.7 The CTDIfilm values were slightly lower than
TG111 which is likely due to a small portion of the dose tail falling
beyond the 30 cm sensitive length of the film, which was also
reported by Hu, by comparing dose profiles measured along the full
45 cm phantom length with 30-cm film strip measurements.
The doses measured in this study were in agreement with stud-
ies carried out using the same methodologies and imaging sys-
tems.5,7,24,25 However, it has to be kept in mind that, depending on
imaging system, software version and methodology, doses varied
greatly from study to study, and this should be taken into account
when interpreting the results.7,10,16,25–29 Additionally, it must be
stressed that doses presented in this work represent average air
KERMA within a PMMA cylindrical phantom and should not be
interpreted as patient dose. Any such conversion to patient dose
would require information regarding the beam spectrum, organ site
and patient size parameters.30
5 | CONCLUSION
The methods evaluated in this work estimate the radiation output of
two kV CBCT imaging systems as average dose to the center of a
PMMA cylindrical phantom; they are therefore used as a tool to
compare radiation exposures from different scanners and/or imaging
protocols. This study investigated how the dose estimated by the
AAPM TG111, the IAEA Report No. 5, and the Cone-Beam Dose
Index protocols, which try to account for higher S–I beam widths
inherent with CBCT imaging, compares to the current standard for
estimation of CT radiation output, the CTDI.
It has been shown that CTDI values systematically measured lower
doses when compared to the three alternative methods; in particular,
they underestimated doses when wider beam widths were considered.
Amongst the protocols investigated, the TG111 method accounts for
the full scatter profile using a longer cylindrical phantom than the other
methods; it is therefore reasonable to consider the dose measured
using the TG111 protocol as the best estimation of dose in the center
of a PMMA phantom from a CBCT acquisition. This was sup-
ported by weighted average kV CBCT dose using CTDIfilm profile mea-
surements. The IAEA methodology agreed with the TG111 estimations
in air, but it was not able to account for the full scatter profile when
measured in a phantom. In the absence of a custom-made full-length
phantom, the CBDI approach gives a comparable indication of CBCT
dose to the TG111 methodology using equipment more commonly
found in radiotherapy departments. Future work should also involve
conversion of TG111 measurements to patient dose, taking into
account patient-specific imaging parameters and patient size.
As a secondary result of this study, it has been shown that, for
the imaging protocols considered, the XI system consistently deliv-
ered lower dose than the OBI system due to its harder energy spec-
trum, in particular when values were normalized to 100 mAs.
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